北京大学学报(医学版) ›› 2015, Vol. 47 ›› Issue (4): 605-610. doi: 10.3969/j.issn.1671-167X.2015.04.011

• 论著 • 上一篇    下一篇

肾移植受者上尿路尿路上皮癌术后膀胱复发的预后因素

刘余庆,卢剑,赵磊,侯小飞,马潞林△   

  1. (北京大学第三医院泌尿外科,北京100191)
  • 出版日期:2015-08-18 发布日期:2015-08-18
  • 通讯作者: 马潞林 E-mail:malulin@medmail.com.cn

Prognostic factors for intravesical recurrence after surgery for upper tract urothelial carcinoma in renal transplant recipients

LIU Yu-qing, LU Jian, ZHAO Lei, HOU Xiao-fei, MA Lu-lin△   

  1. (Department of Urology, Peking University Third Hospital, Beijing 100191, China)
  • Online:2015-08-18 Published:2015-08-18
  • Contact: MA Lu-lin E-mail:malulin@medmail.com.cn

摘要:

目的:评价肾输尿管全长切除术治疗肾移植受者原发上尿路尿路上皮癌(upper tract urothelial carcinoma,UTUC)术后膀胱复发的独立危险因素。方法:回顾2006年4月至2013年3月临床诊断为肾移植后局限性UTUC并且排除既往或同期合并膀胱肿瘤的病例共38例,均接受后腹腔镜下肾输尿管全长切除术。采用Kaplan-Meier方法对临床病理特征、危险因素和术后膀胱无复发生存率进行单因素分析。采用单因素和多因素Cox比例风险回归模型分析影响膀胱肿瘤复发的独立危险因素。结果:本组患者随访时间12~104个月,中位随访时间38个月,其间膀胱复发率42.1%(16/38),其中75.0%复发于术后2年内,手术与复发间隔时间6~48个月,中位复发时间15.5个月。单因素分析显示,原肾为马兜铃酸肾病(aristolochic acid nephropathy,AAN)、肿瘤为多中心和累及输尿管下段可增加膀胱复发风险。术后2年膀胱复发率,原肾AAN组为62.5%(5/8),肿瘤多中心发病组为46.2%(12/26)。多因素分析结果表明,肿瘤多中心发病(HR=2.603,95% CI=1.529~8.906,P=0.019)和原肾马兜铃酸肾病(HR=2.179,95% CI=1.085~8.093,P=0.038)是术后膀胱复发的独立预后危险因素。结论:肾移植受者UTUC经腹腔镜肾输尿管全长切除术后膀胱复发率高,大多数病例于术后2年内复发,多因素分析显示,肿瘤多中心发病和原肾AAN是术后膀胱复发的独立预后危险因素。

关键词: 泌尿道, 癌, 移行细胞, 膀胱肿瘤, 肿瘤复发, 局部, 肾移植

Abstract:

Objective:To elucidate clinicopathological independent prognostic factors for intravesical recurrence after nephroureterectomy for native upper tract urothelial carcinoma (UTUC) in renal transplant recipients. Methods: In this study, 38 patients clinically diagnosed as localized UTUC after renal transplantation were included, and treated by retroperitoneal laparoscopic nephroureterectomy between April 2006 and March 2013, after exclusion of those with a previous and/or concurrent history of bladder cancer. The clinicopathologic features, risk factors, and intravesical recurrence free survival were analyzed using the Kaplan-Meier method. Univariate and multivariate analyses by Cox’s proportional hazards regression model were used to identify independent risk factors for intravesical tumor recurrence. Results: Of all the patients, 16/38 (42.1%) developed subsequent intravesical recurrence during a median follow-up period of 38 months (range 12 to 104 months), of whom, 12/16 (75.0%) developed recurrent bladder cancer within 2 years after nephroureterectomy, and the median interval between surgery and intravesical recurrence was 15.5 months (range 6 to 48 months). Multifocal tumors, native aristolochic acid nephropathy (AAN) and distal ureter involvement were determined as risk factors for intravesical recurrence by univariate analysis. The intravesical recurrence rate was 62.5%(5/8)  in the group of native AAN , and 46.2% (12/26) in the group of multifocality. By multivariate analyses, multifocality (HR=2.603, 95% CI=1.529-8.906, P=0.019) and native AAN (HR=2.179, 95% CI=1.085-8.093, P=0.038) were identified as independent predictors for the development of recurrent bladder cancer after surgery for UTUC in renal transplant recipients. Conclusion: The incidence of intravesical recurrence after laparoscopic nephroureterectomy for UTUC in renal transplant recipients is high, and most subsequent bladder cancers recur within 2 years after surgery. Tumor multifocality and native AAN are significant independent risk factors in developing initial intravesical recurrence after laparoscopic surgery for primary UTUC after renal transplantation.

Key words: Urinary tract, Carcinoma, transitional cell, Urinary bladder neoplasms, Neoplasm recurrence, local, Kidney transplantation

中图分类号: 

  • R737.14
[1] 步召德, 冯梦宇, 季科. 早期胃癌行前哨淋巴结导航手术的实践与思考[J]. 北京大学学报(医学版), 2026, 58(2): 239-243.
[2] 王海, 江一舟. 靶向血管治疗在乳腺癌精准治疗中的分子机制与临床应用[J]. 北京大学学报(医学版), 2026, 58(2): 251-256.
[3] 罗必显, 刘洪铭, 谢伟勋, 龚渭华. 产甲胎蛋白胃癌的新临床特征和前沿科学问题[J]. 北京大学学报(医学版), 2026, 58(2): 257-265.
[4] 付浩, 申潞艳, 黄冰洋, 马少华. 免疫治疗背景下食管鳞状细胞癌围手术期治疗的临床思考[J]. 北京大学学报(医学版), 2026, 58(2): 266-271.
[5] 殷昊明, 王子杰, 舒帆, 张展奕, 梁会, 张树栋. 肾透明细胞癌FABP6基因长转录本的表达及意义[J]. 北京大学学报(医学版), 2026, 58(2): 393-398.
[6] 李嘉临, 陈力侨, 唐家天, 吴艳, 王安强. 胃肝样腺癌转化治疗1例[J]. 北京大学学报(医学版), 2026, 58(2): 399-404.
[7] 郭芷均, 俎明, 马超, 张贺军, 张静, 丁士刚. 同时性多发早期胃癌漏诊病灶的临床病理特征[J]. 北京大学学报(医学版), 2026, 58(2): 410-415.
[8] 潘子晨, 陈凯, 侯钰坤, 杨博涵, 张继新, 马永蔌, 田孝东, 杨尹默. 胰腺腺鳞癌临床病理特征与分子机制研究进展[J]. 北京大学学报(医学版), 2026, 58(2): 431-435.
[9] 张铃福, 陈明, 赵小宇, 王港, 崔龙, 凌晓锋, 王立新, 徐智, 郭丽梅, 侯纯升. 原发灶局限于胆囊壁内胆囊癌大体分型及其与预后和癌前病变的相关性[J]. 北京大学学报(医学版), 2026, 58(1): 184-189.
[10] 王晓林, 李璐瑶, 张雯, 王鸿雁. 3例子宫体中肾样腺癌的临床病理学分析[J]. 北京大学学报(医学版), 2025, 57(6): 1208-1212.
[11] 侯卫华, 宋书杰, 石中月, 刘露, 金木兰. 食管胃结合部具有显著空泡状核特征的神经内分泌癌1例[J]. 北京大学学报(医学版), 2025, 57(5): 1005-1009.
[12] 谢尚, 王鹿鸣, 张馨元, 冯秋实, 夏洋洋, 戴姿薇, 单小峰, 蔡志刚. 口腔鳞癌类器官库的构建及应用[J]. 北京大学学报(医学版), 2025, 57(5): 847-851.
[13] 李浙民, 季加孚, 李国新, 李子禹, 步召德, 高翔宇, 董迪, 唐磊, 邢晓芳, 贾淑芹, 郭婷, 张连海, 陕飞, 季鑫, 王安强. 胃癌精准诊疗技术的创建与推广[J]. 北京大学学报(医学版), 2025, 57(5): 864-867.
[14] 唐少海, 杨宝明, 李建坤, 赵丽丽, 王仪凡, 王顺祥. HDAC2介导H3K27ac修饰促进肝癌细胞的增殖和迁移[J]. 北京大学学报(医学版), 2025, 57(5): 884-894.
[15] 杨小勇, 张帆, 马潞林, 刘承. 前列腺导管腺癌临床特征及腺外侵犯的影响因素[J]. 北京大学学报(医学版), 2025, 57(5): 956-960.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!